GI
IOVA icon

GAMMA Investing’s Iovance Biotherapeutics IOVA Stock Holding History

GAMMA Investing’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6K Buy
5,422
+9
+0.2% +$34 ﹤0.01% 2777
2026
Q1 		$19K Buy
5,413
+2,600
+92% +$8.32K ﹤0.01% 2740
2025
Q4 		$7.68K Buy
+2,813
New +$6.51K ﹤0.01% 3103
2025
Q2 		– Sell
-1,990
Closed -$6.63K – 3835
2025
Q1 		$6.63K Buy
1,990
+804
+68% +$4.15K ﹤0.01% 2948
2024
Q4 		$8.78K Buy
1,186
+188
+19% +$1.74K ﹤0.01% 2677
2024
Q3 		$9.37K Sell
998
-1,729
-63% -$16.4K ﹤0.01% 2491
2024
Q2 		$21.9K Buy
2,727
+1,938
+246% +$20.8K ﹤0.01% 1793
2024
Q1 		$11.7K Buy
789
+224
+40% +$2.61K ﹤0.01% 1977
2023
Q4 		$4.37K Buy
+565
New +$2.96K ﹤0.01% 2297

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GAMMA Investing's IOVA Position: Q2 2026 in Review

GAMMA Investing increased its Iovance Biotherapeutics (IOVA) stake by 0.17% in Q2 2026, buying an estimated $34 and bringing the position to 5,422 shares worth $22.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2777.

GAMMA Investing first reported a position in IOVA in Q4 2023 and has held it in 9 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • GAMMA Investing held 5,422 shares of Iovance Biotherapeutics worth $22.6K as of Q2 2026.
  • GAMMA Investing bought 9 Iovance Biotherapeutics shares in Q2 2026, an estimated $34.
  • Iovance Biotherapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2777 holding.
  • GAMMA Investing first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 9 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.